193 related articles for article (PubMed ID: 25866336)
21. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K; Brennan DC
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions.
Razonable RR
Curr Pharm Des; 2020; 26(28):3497-3506. PubMed ID: 32473617
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus appendicitis in an immunocompetent host.
Canterino JE; McCormack M; Gurung A; Passarelli J; Landry ML; Golden M
J Clin Virol; 2016 May; 78():9-11. PubMed ID: 26942831
[TBL] [Abstract][Full Text] [Related]
24. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.
Gracia-Ahufinger I; Gutiérrez-Aroca J; Cordero E; Vidal E; Cantisán S; del Castillo D; Martín-Gandul C; Rivero A; Torre-Cisneros J
Transplantation; 2013 Apr; 95(8):1015-20. PubMed ID: 23407543
[TBL] [Abstract][Full Text] [Related]
25. Relapsing cytomegalovirus infection in solid organ transplant recipients.
Shanahan A; Malani PN; Kaul DR
Transpl Infect Dis; 2009 Dec; 11(6):513-8. PubMed ID: 19735385
[TBL] [Abstract][Full Text] [Related]
26. Increased osteoprotegerin predicts poor virological outcome during anticytomegalovirus therapy in solid organ transplant recipients.
Ueland T; Rollag H; Hartmann A; Jardine A; Humar A; Bignamini AA; Åsberg A; Aukrust P
Transplantation; 2015 Jan; 99(1):100-5. PubMed ID: 24983306
[TBL] [Abstract][Full Text] [Related]
27. Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
Fisher CE; Alexander J; Bhattacharya R; Rakita RM; Kirby KA; Boeckh M; Limaye AP
Transpl Infect Dis; 2016 Jun; 18(3):372-80. PubMed ID: 27004439
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus myocarditis in solid organ transplant recipients: A case series and review of literature.
Scherger S; Mathur S; Bajrovic V; Johnson SC; Benamu E; Ramanan P; Wolfel G; Levi ME; Abidi MZ
Transpl Infect Dis; 2020 Jun; 22(3):e13282. PubMed ID: 32232951
[TBL] [Abstract][Full Text] [Related]
29. [Gastrointestinal cytomegalovirus infections in organ transplant patients].
Péter A; Telkes G; Varga M; Járay J
Orv Hetil; 2008 Dec; 149(52):2463-70. PubMed ID: 19087914
[TBL] [Abstract][Full Text] [Related]
30. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
[TBL] [Abstract][Full Text] [Related]
31. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
32. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.
Navarro D; San-Juan R; Manuel O; Giménez E; Fernández-Ruiz M; Hirsch HH; Grossi PA; Aguado JM;
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28859257
[TBL] [Abstract][Full Text] [Related]
33. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
34. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.
Manuel O; Perrottet N; Pascual M
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):955-65. PubMed ID: 22029513
[TBL] [Abstract][Full Text] [Related]
35. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.
Bounaadja L; Piret J; Goyette N; Boivin G
J Clin Virol; 2013 Sep; 58(1):279-82. PubMed ID: 23871165
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation.
Sia IG; Wilson JA; Groettum CM; Espy MJ; Smith TF; Paya CV
J Infect Dis; 2000 Feb; 181(2):717-20. PubMed ID: 10669361
[TBL] [Abstract][Full Text] [Related]
37. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
38. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.
Limaye AP
Semin Respir Infect; 2002 Dec; 17(4):265-73. PubMed ID: 12497543
[TBL] [Abstract][Full Text] [Related]
39. Human cytomegalovirus and kidney transplantation: a clinician's update.
De Keyzer K; Van Laecke S; Peeters P; Vanholder R
Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
[TBL] [Abstract][Full Text] [Related]
40. Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.
Koval CE
Infect Dis Clin North Am; 2018 Sep; 32(3):581-597. PubMed ID: 30146024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
